Andrew Blauvelt

416 total citations
16 papers, 242 citations indexed

About

Andrew Blauvelt is a scholar working on Dermatology, Immunology and Oncology. According to data from OpenAlex, Andrew Blauvelt has authored 16 papers receiving a total of 242 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Dermatology, 8 papers in Immunology and 4 papers in Oncology. Recurrent topics in Andrew Blauvelt's work include Dermatology and Skin Diseases (8 papers), Psoriasis: Treatment and Pathogenesis (6 papers) and Asthma and respiratory diseases (4 papers). Andrew Blauvelt is often cited by papers focused on Dermatology and Skin Diseases (8 papers), Psoriasis: Treatment and Pathogenesis (6 papers) and Asthma and respiratory diseases (4 papers). Andrew Blauvelt collaborates with scholars based in United States, Canada and Germany. Andrew Blauvelt's co-authors include Mark C. Udey, Pamela Cook, Shizuko Sei, Thomas F. Schulz, Kuan‐Teh Jeang, William Martel, Charles N. Ellis, Brian Calimlim, Samantha Eisman and Vimal H. Prajapati and has published in prestigious journals such as The Journal of Infectious Diseases, Journal of Investigative Dermatology and Journal of the American Academy of Dermatology.

In The Last Decade

Andrew Blauvelt

12 papers receiving 235 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Blauvelt United States 8 94 77 68 68 52 16 242
C. Masini Italy 8 58 0.6× 85 1.1× 127 1.9× 120 1.8× 50 1.0× 11 292
Paulo Varela Portugal 9 43 0.5× 77 1.0× 30 0.4× 64 0.9× 27 0.5× 33 177
P. Berbis France 11 64 0.7× 90 1.2× 27 0.4× 48 0.7× 39 0.8× 32 269
Cayetana Maldonado-Seral Spain 5 118 1.3× 126 1.6× 62 0.9× 70 1.0× 18 0.3× 7 262
K. E. Johnson United States 9 174 1.9× 52 0.7× 113 1.7× 106 1.6× 32 0.6× 14 371
Kristin Hollister United States 8 274 2.9× 68 0.9× 35 0.5× 18 0.3× 26 0.5× 14 338
John S. Barber United States 6 146 1.6× 14 0.2× 37 0.5× 19 0.3× 32 0.6× 6 209
Anne Dormoy France 11 383 4.1× 66 0.9× 59 0.9× 63 0.9× 11 0.2× 30 547
Julia Prinz Germany 9 163 1.7× 257 3.3× 28 0.4× 43 0.6× 22 0.4× 22 431
Sabra Sullivan United States 10 232 2.5× 129 1.7× 29 0.4× 66 1.0× 14 0.3× 12 394

Countries citing papers authored by Andrew Blauvelt

Since Specialization
Citations

This map shows the geographic impact of Andrew Blauvelt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Blauvelt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Blauvelt more than expected).

Fields of papers citing papers by Andrew Blauvelt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Blauvelt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Blauvelt. The network helps show where Andrew Blauvelt may publish in the future.

Co-authorship network of co-authors of Andrew Blauvelt

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Blauvelt. A scholar is included among the top collaborators of Andrew Blauvelt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Blauvelt. Andrew Blauvelt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Armstrong, April W., et al.. (2025). Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis. British Journal of Dermatology. 193(3). 442–450.
2.
Reich, Kristian, Richard G. Langley, J.F. Silvestre, et al.. (2025). Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials. British Journal of Dermatology. 194(2). 225–235.
3.
Blauvelt, Andrew, Petr Arenberger, Maxwell Sauder, et al.. (2025). Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study. Journal of the American Academy of Dermatology. 94(1). 57–65. 2 indexed citations
4.
5.
Merola, Joseph F., Kim Papp, Atul Deodhar, et al.. (2025). Ixekizumab and Malignant Neoplasms. JAMA Dermatology. 161(10). 1048–1048.
6.
Lebwohl, Mark, Bruce Strober, Amy Schrader, et al.. (2024). Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes. 11(3). 451–464. 2 indexed citations
7.
Blauvelt, Andrew, Yang Zhao, Marci Clark, et al.. (2024). Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews. British Journal of Dermatology. 192(2). 247–260. 2 indexed citations
8.
Blauvelt, Andrew, Phoebe Rich, Howard Sofen, et al.. (2023). Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis. Journal of the American Academy of Dermatology. 90(4). 775–782. 12 indexed citations
9.
Veverka, Karen A., Steven Tien Guan Thng, Jonathan I. Silverberg, et al.. (2023). Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study. Journal of the American Academy of Dermatology. 90(3). 504–511. 12 indexed citations
10.
Blauvelt, Andrew, Barry Ladizinski, Vimal H. Prajapati, et al.. (2023). Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). Journal of the American Academy of Dermatology. 89(3). 478–485. 23 indexed citations
11.
Blauvelt, Andrew, Mark Lebwohl, Richard G. Langley, et al.. (2023). Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology. 89(2). 274–282. 12 indexed citations
12.
Reich, Kristian, Jacob P. Thyssen, Andrew Blauvelt, et al.. (2023). Comparing how Well Abrocitinib and Dupilumab Treat Atopic Dermatitis Signs and Symptoms: A Plain Language Summary. Immunotherapy. 15(13). 975–980. 4 indexed citations
13.
Blauvelt, Andrew, Shizuko Sei, Pamela Cook, Thomas F. Schulz, & Kuan‐Teh Jeang. (1997). Human Herpesvirus 8 Infection Occurs following Adolescence in the United States. The Journal of Infectious Diseases. 176(3). 771–774. 63 indexed citations
14.
Blauvelt, Andrew, et al.. (1995). Human Langerhans Cells Express E-Cadherin. Journal of Investigative Dermatology. 104(2). 293–296. 70 indexed citations
15.
Blauvelt, Andrew, et al.. (1995). The Skin as Target, Vector, and Effector Organ in Human Immunodeficiency Virus Disease. Journal of Investigative Dermatology. 105(1). S122–S126. 16 indexed citations
16.
Ellis, Charles N., et al.. (1988). Long-term radiographic follow-up after isotretinoin therapy. Journal of the American Academy of Dermatology. 18(6). 1252–1261. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Masini Breakdown of academic impact, for papers by Paulo Varela Breakdown of academic impact, for papers by P. Berbis Breakdown of academic impact, for papers by Cayetana Maldonado-Seral Breakdown of academic impact, for papers by K. E. Johnson Breakdown of academic impact, for papers by Kristin Hollister Breakdown of academic impact, for papers by John S. Barber Breakdown of academic impact, for papers by Anne Dormoy Breakdown of academic impact, for papers by Julia Prinz Breakdown of academic impact, for papers by Sabra Sullivan
Rankless by CCL
2026